Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Samsara Inc (IOT) vs Smith & Nephew plc (SNN) Price & Performance

Samsara IncTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Samsara Inc vs Smith & Nephew plc — how do they compare? Samsara Inc trades at $36.79 (market cap $22.46B), while Smith & Nephew plc trades at $30.15 (market cap $12.64B). The key difference: Samsara Inc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.57% dividend while Samsara Inc pays none. Which is the better fit depends on your goals.

IOTSNN
Market Cap
$22.46B$12.64B
Sector
TechnologyHealth
52-Week High
$45.22$38.70
52-Week Low
$24.25$28.73
Enterprise Value
$21.73B$15.41B
Dividend Yield
2.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Samsara Inc

Samsara (IOT) trades at $38.55, up 0.6% with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings momentum with three consecutive quarterly beats, while revenue growth accelerated to $1.7B in 2026 with positive net income of $58M. Technical indicators show bullish moving averages despite overbought RSI readings, with key resistance at $39-$41. Recent product launches including AI agentic tools and tracking labels demonstrate continued innovation in connected operations.

The outlook remains positive with 78% analyst buy ratings and $44.40 consensus target offering 15% upside. However, elevated valuations (P/E 383) and negative 2025 cash flow (-$59M) present risks. Growth sustainability depends on maintaining large customer momentum and margin expansion amid AI investments. The stock presents a growth opportunity but requires monitoring of execution and valuation compression risks.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $30.43, down 0.54% on the day, with mixed technical signals showing a neutral overall stance. The company demonstrates improving fundamentals with 2024 revenue of $5.81 billion and net income of $412 million, representing a 7.09% margin. Recent product launches including the LYNX COBLATION Wand and CORI XT robotics platform highlight ongoing innovation. Cash flow trends show strong operational performance with $987 million from operations in 2024.

SNN presents a balanced investment case with improving profitability and product innovation offset by recent earnings misses. The stock trades at reasonable valuations (P/E 21.36, P/S 2.17) with analyst consensus leaning Hold (68%). Key risks include execution challenges and competitive pressures, while catalysts include robotics expansion and wound care leadership. The $500 million buyback program supports shareholder returns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Samsara Inc

Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.

Read more on IOT

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN